. 2013 Sep 1;7(5):1354–1358. doi: 10.1177/193229681300700527

Table 1.

Characteristics of Type 2 Diabetes Patients with Prescriptions of Glargine, Detemir, or NPH Insulin in Primary Care Practices: Disease Analyzer, Germany [May 2009–April 2012; Data in Means (Standard Deviation) or proportions (%)]

Variables	Glargine	Total: Detemir	NPH insulin	Glargine	BOT: Detemir	NPH insulin	Glargine	ICT: Detemir	NPH insulin
N	4211	1290	3876	2247	490	1331	1964	800	2545
Age (years)	70.2 (11.3)^a,b	66.7 (11.7)^a	69.0 (10.9)^b	71.1 (11.3)^a,a	6 7.1 ( 11. 7 ) ^a	6 9 . 6 (11. 2) ^b	68.4 (11.0)^a	6 5 .7 (11. 4 ) ^a	68.5 (10.8)
Males (%)	51.6	51.1	52.1	51.4	49.3	53.0	51.7	52.2	51.9
Private health insurance (%)	4.9^b	5.4	2.9^b	5.7^b	6.5	3.0^b	4 .1^b	4.7	2.9^b
Diabetologist treatment (%)	17. 0 ^b	16.9	26.5^b	11. 2 ^b	12.0	20.0^b	24.6^b	20.6	30.3^b
Region (West Germany) (%)	61.9^a,b	65.5^a	62.7^b	66.8	68.6	69.5	56.6^a	64.2^a	58.7
Urban residency^c (%)	24.4^a,b	2 1.1 ^a	22.3^b	26.3^b	25.6	23.0^b	2 2.1^a	18 .1^a	21.7
Charlson comorbidity score	2.3 (1.6)	2.3 (1.5)	2.3 (1.5)	2.1 (1.6)	2.2 (1.6)	2.1 (1.4)	2.4 (1.6)	2.4 (1.4)	2.3 (1.5)
Daily insulin dosage (IU)	22.7 (14.0)^a,b	26.0 (17.0)^a	24.3 (15.9)^b	20.5 (13.0)^a	22.7 (14.8)^a	21.6 (14.9)	25.9 (14.7 )^a	28.5 (18.2)^a	25.8 (16.1)
HbA1c (%) ^d	7. 8 (1. 3 ) ^a	8 .1 (1. 4) ^a	7.9 (1.3)	7. 9 (1. 3 ) ^a	7. 8 (1. 2) ^a	7.8 (1.2)	7. 9 (1. 3) ^a	8.2 (1.5)^a	7.9 (1.4)
BMI (kg/m²)^e	31.1 ( 5 .6 ) ^b	31.8 (5.9)	32.0 (5.6)^b	30.9 (5.5)	31.6 (5.5)	31.6 (5.5)	31.4 (5.6)^b	32.5 (5.9)	32.3 (5.7)^b

p < .05 glargine versus detemir.

p < .05 glargine versus NPH.

>100,000 inhabitants.

Recorded values: glargine n = 2858, detemir n = 937, NPH n = 2651.

Recorded values: glargine n = 1177, detemir n = 381, NPH n = 11 9 3 .